Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating safety, pharmacokinetics, and pharmacodynamics of MK-8876 in participants with hepatitis C infection has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-8876

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2016-02-04